SCHEMBL24747237

SCHEMBL24747237

Nc1ccc(N2CCCC(F)C2)cn1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.40
CHRNA4 P43681 3/20 0.40
LRRK2 Q5S007 3/20 0.37
DEGS1 O15121 1/20 0.37
CHRM3 P20309 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
MAPT P10636 2/20 0.36
GCK P35557 1/20 0.35
GCKR Q14397 1/20 0.35
PIK3CA P42336 2/20 0.35
MTOR P42345 2/20 0.35
PIK3R1 P27986 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30316329 1.00 CHRNB2 (0.40) CHRNB2CHRNA4LRRK2DEGS1CHRM3
SCHEMBL18291319 0.83 MAPT (0.48) CHRNB2CHRNA4MAPTGCKGCKR
SCHEMBL18779659 0.83 MAP4K4 (0.46) CHRNB2CHRNA4ALOX5APFEN1
SCHEMBL30316041 0.81 SMPD3 (0.47) CHRNB2CHRNA4LRRK2ALOX5APFEN1
SCHEMBL17799085 0.81 SMPD3 (0.47) CHRNB2CHRNA4LRRK2ALOX5APFEN1
SCHEMBL30316026 0.81 SMPD3 (0.47) CHRNB2CHRNA4LRRK2ALOX5APFEN1
SCHEMBL17796348 0.81 SMPD3 (0.47) CHRNB2CHRNA4LRRK2ALOX5APFEN1
SCHEMBL25065178 0.81 MAP4K4 (0.47) CHRNB2CHRNA4LRRK2MAPT
SCHEMBL24746250 0.81 SLC6A9 (0.41) CHRNB2CHRNA4LRRK2DEGS1CHRM3
SCHEMBL17054803 0.81 SMPD3 (0.47) CHRNB2CHRNA4LRRK2ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230096641-A1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-30 US disclosed
WO-2022174253-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230096641-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 CHRNB2 3697/4885CHRNA4 4574/4885LRRK2 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.